The first domestic new crown oral medication was temporarily included in medical insurance reimbursement

The first domestic new crown oral medication was temporarily included in medical insurance reimbursement

Insurance patients can pay for the medical insurance fund when using the Azf fixed film

Yesterday, the National Medical Insurance Bureau stated that the first domestic new crown oral medication can be temporarily included in medical insurance reimbursement.

The State Medical Insurance Bureau pointed out that in accordance with the relevant provisions of basic medical insurance, in order to better protect the needs of diagnosis and treatment, all drugs included in the new coronary pneumonia diagnosis and treatment plan can be temporarily included in the scope of medical insurance payment. On August 9, the National Health Commission has issued a notice to include Azf's fixed slices into the new type of coronary virus pneumonia diagnosis and treatment plan. Therefore, the medical insurance fund can be paid in accordance with regulations when using the drug.

According to reports, on August 11, Fosun Pharmaceutical announced that the company combined with real biological in response to the needs of governments in various localities, and urgently arranged anti -new crown pneumonia small molecules oral drugs, Azf, to support many places across the country, and recently arrived in Henan and Hainan. , Xinjiang and other places. According to the price of medical insurance networks in various places, Azf's fixed price is priced at 270 yuan per bottle, 35 tablets per bottle, and 1 mg per piece.

On July 25, Fosun Pharmaceutical announced a strategic cooperation with Henan Real Biotechnology Co., Ltd., which will jointly develop and be exclusively commercialized by the holding subsidiary Fosun Pharmaceutical Industry. Fosun Pharmaceutical will continue to pay close attention to the situation of this round of epidemic, and has made corresponding commercial deployments, and cooperates with partners to ensure the production and supply of drugs, and effectively meet the needs of the first -line prevention and control of the epidemic.

It is understood that Azf's fixed tablet is the treatment of oral small molecular virus pneumonia therapy drugs independently developed by my country. Phase III registered clinical trials that support their listing applications show that Azf's fixed tablet can significantly shorten the moderate improvement time of patients with pneumonia infected with pneumonia, and increase the proportion of patients with improvement of clinical symptoms and achieve clinical excellent results.

In terms of inhibiting the role of new coronal virus, Azf will definitely inhibit the activity of the new coronal virus. In addition, from the perspective of security, the overall tolerance of Azf's fixed decision, the incidence of adverse events has no statistical differences with the placebo group, and the risk of the subject has not increased.

On July 20, 2021, the State Drug Administration has attached conditions to approve this product and other reverse-translitease inhibitors to treat adult HIV-1 infection patients with high virus load. On July 25, 2022, the Emergency Conditions of the State Drug Administration approved the real creature Azf fixed tablet to increase the application of new coronary pneumonia treatment indications for the treatment of adult patients with COVID-19). On August 9th, the General Office of the National Health and Health Commission and the Office of the State Administration of Traditional Chinese Medicine issued a notice saying that the approved opinions of the application for the treatment of new coronary virus pneumonia are approved in accordance with the conditions of the State Drug Administration. Improve the new type of coronary virus pneumonia antiviral treatment plan. After research, the medicine is included in the "New Coronatte Pneumonia Pneumonia Diagnosis and Treatment Plan (Ninth Edition)". According to the "diagnosis and treatment plan", Azf's fixed tablet is used to treat adult patients with COVID-19). The amount of usage is swallowed by the entire space, 5mg each time, once a day, the course of treatment is not more than 14 days.

This is an attachment to approve new indications for the treatment of adult patients with COVID-19) for the treatment of ordinary new type of coronary virus pneumonia. Patients should be used strictly under the guidance of the doctor. (Reporter Xie Li Zhang Xin)

(Xie Li Zhang Xin)

- END -